Novartis Ag (NVS) Prepaid Assets (2009 - 2026)

Novartis Ag (NVS) posted Prepaid Assets of $100.0 million for Q1 2026, down 91.33% sequentially from $1.2 billion in Q4 2025.

Novartis Ag (NVS) Prepaid Assets (2009 - 2026) Analysis & Trends

Novartis Ag has reported Prepaid Assets for 18 years, with the latest figure at $100.0 million in Q1 2026.

Quarterly Prepaid Assets changed N/A year-over-year to $100.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.0 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 billion, up 88.09% from the prior year.
Prepaid Assets fell to $100.0 million in Q1 2026 per NVS's latest filing, from $1.2 billion in the prior quarter.
Over five years, Prepaid Assets peaked at $3.5 billion in Q2 2025 and troughed at $5.0 million in Q1 2022.
A 5-year average of $1.6 billion and a median of $1.8 billion in 2022 frame the typical range for Prepaid Assets.
The sharpest annual moves came in 2022 and 2023: Prepaid Assets tumbled 99.81% in 2022, then surged 56460.0% in 2023.
Over 5 years, Prepaid Assets stood at $2.5 billion in 2022, then rose by 5.5% to $2.6 billion in 2023, then tumbled by 76.49% to $613.0 million in 2024, then jumped by 88.09% to $1.2 billion in 2025, then tumbled by 91.33% to $100.0 million in 2026.
According to Business Quant data, Prepaid Assets over the past three periods registered $100.0 million, $1.2 billion, and $3.5 billion for Q1 2026, Q4 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data